PHE issues guide on sepsis in children for health visitors and school nurses

PHE issues guide on sepsis in children for health visitors and school nurses

October 10 2017 A new guide setting out information around sepsis in children has been published...

MHRA issues Drug Safety Updates for loperamide and miconazole

MHRA issues Drug Safety Updates for loperamide and miconazole

October 4 2017 The medicines regulator, the MHRA, has issued Drug Safety Updates on two...

Pregnant women are still not being informed of risks associated with sodium valproate

Pregnant women are still not being informed of risks associated with sodium valproate

September 26 2017 Almost a fifth of women with epilepsy (18%) who take sodium valproate are not...

Accu-Chek Insight insulin pumps in MHRA alert over risk of alarm failure

Accu-Chek Insight insulin pumps in MHRA alert over risk of alarm failure

September 25 2017 Users of the Accu-Chek Insight insulin pumps are being asked to check their...

Flu vaccine for 2016-17 season not considered effective in the over 65s age group

Flu vaccine for 2016-17 season not considered effective in the over 65s age group

September 6 2017 Provisional figures for vaccine effectiveness in the 2016-17 flu season have...

  • PHE issues guide on sepsis in children for health visitors and school nurses

    PHE issues guide on sepsis in children for health visitors and school nurses

    Tuesday, 10 October 2017 13:34
  • MHRA issues Drug Safety Updates for loperamide and miconazole

    MHRA issues Drug Safety Updates for loperamide and miconazole

    Wednesday, 04 October 2017 17:04
  • Pregnant women are still not being informed of risks associated with sodium valproate

    Pregnant women are still not being informed of risks associated with sodium valproate

    Tuesday, 26 September 2017 15:51
  • Accu-Chek Insight insulin pumps in MHRA alert over risk of alarm failure

    Accu-Chek Insight insulin pumps in MHRA alert over risk of alarm failure

    Monday, 25 September 2017 14:26
  • Flu vaccine for 2016-17 season not considered effective in the over 65s age group

    Flu vaccine for 2016-17 season not considered effective in the over 65s age group

    Wednesday, 06 September 2017 16:53

drugalertJune 29 2016

Adempas (riociguat) should not be used in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia or PH-IIP, the European Medicines Agency has warned.

Although the drug is not authorised for use in PH-IIP patients, the EMA has issued the recommendation following the early termination of a phase II clinical trial, RISE-IIP, investigating the effects of Adempas in this patient population.

“Preliminary results showed an increased number of deaths and serious adverse events, including breathing problems and lung infections, with Adempas compared with placebo. The available data do not indicate a clinically significant benefit from Adempas treatment in these patients,” said the EMA’s announcement, published on June 24.

The trial had been assessing the medicine in 145 PH-IIP patients, with the primary endpoint being the change in the 6-minute walking distance test after 6 months of treatment. “At the time of the interim assessment leading to the termination of the trial, 21 deaths had been observed, 17 patients taking Adempas and 4 patients taking placebo. Serious adverse events, which were mostly respiratory disease or lung infections, were also higher among patients taking Adempas.”

EMA is advising health professionals that “if any patients with PH-IIP are being treated with Adempas, this treatment should be discontinued and the patient’s clinical status carefully monitored.” A contraindication will also be included in prescribing information, and EMA will be issuing a letter to health professionals. 

It has also stated that Adempas continues to have a positive benefit-risk balance for its authorised uses.

The product’s indications in the UK are:

  • treating adults with WHO Functional Class (FC) II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity
  • as monotherapy or in combination with endothelin receptor antagonists for adults with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.

Links:

EMA announcement

Adempas SPC on eMC

Clinical News

October 20 2017 Recruitment to GP training places in Wales has meant 91% of places were filled in 2017, the Welsh Government has announced. The success means that the recruitment campaign ‘This is...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...